Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

114921 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-25

Study Completion Date

2023-09-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to describe initiation and use of oxygen therapy among patients with fibrotic Interstitial Lung Disease (ILD) and to assess the impact of oxygen therapy on clinical outcomes among patients with fibrotic ILD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FIBRotic Interstitial Lung Disease and Nocturnal OXygen

NCT04586946

Idiopathic Pulmonary Fibrosis Obstructive Sleep Apnea Sleep Disturbance +1 more

COMPLETED

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

NCT00470327

Interstitial Lung Diseases Idiopathic Pulmonary Fibrosis Sarcoidosis +1 more

RECRUITING

Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment

NCT05875532

Lung Diseases, Interstitial

COMPLETED

Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT02058602

Idiopathic Pulmonary Fibrosis

COMPLETED PHASE1

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

NCT03261037

Idiopathic Pulmonary Fibrosis Interstitial Lung Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Diseases, Interstitial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with fibrotic interstitial lung disease (ILD)

Patients aged ≥18 years with ≥2 fibrosing ILD diagnoses and continuous enrollment with medical and pharmacy coverage for 12 months prior to the fibrosing ILD diagnosis date as recorded in a commercial, Medicaid, or Medicare plan, using existing administrative claims and EHR data in Optum's Market Clarity Integrated Claims + Clinical database for the patient identification period (01-Oct-2016 through 30-Jun-2022).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥2 fibrosing Interstitial Lung Disease (ILD) diagnoses in any position on different dates of service, within 365 days of each other, and in the same continuous enrollment period during the patient identification period. The fibrosing ILD diagnosis date will be defined as the date of the first fibrosing ILD diagnosis. The two fibrosing ILD diagnosis codes can be one of the following combinations:
* 2 fibrosis codes
* 1 fibrosis code \& 1 ILD code that requires fibrosis code
* ≥18 years of age as of the fibrosing ILD diagnosis date
* Continuous enrollment with medical and pharmacy coverage for 12 months prior to the fibrosing ILD diagnosis date (pre-ILD baseline period)